NVAX:NASDAQ
Novavax Inc
$12.82
arrow_upward
+1.26%(+0.16) 1D
$12.84
arrow_upward
+0.16% (+0.020)bedtimeAfter hours
Closed: Oct 13, 4:00:00 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NVAX...
Open
$12.44
High
$13.12
Low
$12.21
Mkt. cap
2.11B
Avg. vol.
7.43M
Volume
8.40M
52-wk high
$13.38
52-wk low
$6.20
EPS
-$1.52
Beta
2.44
Shares outstanding
164.95M
No. of employees
749
Open
$12.44
High
$13.12
Low
$12.21
Mkt. cap
2.11B
Avg. vol.
7.43M
Volume
8.40M
52-wk high
$13.38
52-wk low
$6.20
EPS
-$1.52
Beta
2.44
Shares outstanding
164.95M
No. of employees
749
News stories
From web sources and news partners
News Corp
·
6 hours ago
Novavax Inc. stock outperforms competitors on strong trading day
Profile
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria.
Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine. Wikipedia
About Novavax Inc
CEOJohn C. Jacobs
Employees749
Founded1987
HeadquartersGaithersburg, Maryland, United States
SectorBiotechnology
Websitenovavax.com